Clonidine plus haloperidol in the treatment of schizophrenia/psychosis

J. W. Maas, Alexander L Miller, J. L. Tekell, L. Funderburg, J. A. Silva, J. True, Dawn I Velligan, N. Berman, C. L. Bowden

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Because of the evidence for increased norepinephrine (NE) production in psychotic patients, we studied the effects of combining the α2-adrenergic agonist clonidine with haloperidol for the treatment of schizophrenic psychosis. Twelve hospitalized schizophrenic patients were taken off their antipsychotic medication for 2 to 4 weeks before double-blind treatment with haloperidol (20 mg/day) combined with either clonidine or placebo. The group receiving clonidine was significantly more improved on the thought disorder subscale of the Brief Psychiatric Rating Scale (p = 0.02). The groups differed initially in the level of negative symptoms, but controlling for this difference statistically by analysis of covariance did not change the finding with regard to the superiority of combining clonidine with haloperidol. We conclude that larger treatment trials of combining haloperidol with clonidine are warranted.

Original languageEnglish (US)
Pages (from-to)361-364
Number of pages4
JournalJournal of Clinical Psychopharmacology
Volume15
Issue number5
DOIs
StatePublished - 1995

Fingerprint

Clonidine
Haloperidol
Psychotic Disorders
Schizophrenia
Brief Psychiatric Rating Scale
Therapeutics
Adrenergic Agonists
Antipsychotic Agents
Norepinephrine
Placebos

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Maas, J. W., Miller, A. L., Tekell, J. L., Funderburg, L., Silva, J. A., True, J., ... Bowden, C. L. (1995). Clonidine plus haloperidol in the treatment of schizophrenia/psychosis. Journal of Clinical Psychopharmacology, 15(5), 361-364. https://doi.org/10.1097/00004714-199510000-00009

Clonidine plus haloperidol in the treatment of schizophrenia/psychosis. / Maas, J. W.; Miller, Alexander L; Tekell, J. L.; Funderburg, L.; Silva, J. A.; True, J.; Velligan, Dawn I; Berman, N.; Bowden, C. L.

In: Journal of Clinical Psychopharmacology, Vol. 15, No. 5, 1995, p. 361-364.

Research output: Contribution to journalArticle

Maas, JW, Miller, AL, Tekell, JL, Funderburg, L, Silva, JA, True, J, Velligan, DI, Berman, N & Bowden, CL 1995, 'Clonidine plus haloperidol in the treatment of schizophrenia/psychosis', Journal of Clinical Psychopharmacology, vol. 15, no. 5, pp. 361-364. https://doi.org/10.1097/00004714-199510000-00009
Maas, J. W. ; Miller, Alexander L ; Tekell, J. L. ; Funderburg, L. ; Silva, J. A. ; True, J. ; Velligan, Dawn I ; Berman, N. ; Bowden, C. L. / Clonidine plus haloperidol in the treatment of schizophrenia/psychosis. In: Journal of Clinical Psychopharmacology. 1995 ; Vol. 15, No. 5. pp. 361-364.
@article{cab2a8d26ad94bc98f32536fc4e4d7d0,
title = "Clonidine plus haloperidol in the treatment of schizophrenia/psychosis",
abstract = "Because of the evidence for increased norepinephrine (NE) production in psychotic patients, we studied the effects of combining the α2-adrenergic agonist clonidine with haloperidol for the treatment of schizophrenic psychosis. Twelve hospitalized schizophrenic patients were taken off their antipsychotic medication for 2 to 4 weeks before double-blind treatment with haloperidol (20 mg/day) combined with either clonidine or placebo. The group receiving clonidine was significantly more improved on the thought disorder subscale of the Brief Psychiatric Rating Scale (p = 0.02). The groups differed initially in the level of negative symptoms, but controlling for this difference statistically by analysis of covariance did not change the finding with regard to the superiority of combining clonidine with haloperidol. We conclude that larger treatment trials of combining haloperidol with clonidine are warranted.",
author = "Maas, {J. W.} and Miller, {Alexander L} and Tekell, {J. L.} and L. Funderburg and Silva, {J. A.} and J. True and Velligan, {Dawn I} and N. Berman and Bowden, {C. L.}",
year = "1995",
doi = "10.1097/00004714-199510000-00009",
language = "English (US)",
volume = "15",
pages = "361--364",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Clonidine plus haloperidol in the treatment of schizophrenia/psychosis

AU - Maas, J. W.

AU - Miller, Alexander L

AU - Tekell, J. L.

AU - Funderburg, L.

AU - Silva, J. A.

AU - True, J.

AU - Velligan, Dawn I

AU - Berman, N.

AU - Bowden, C. L.

PY - 1995

Y1 - 1995

N2 - Because of the evidence for increased norepinephrine (NE) production in psychotic patients, we studied the effects of combining the α2-adrenergic agonist clonidine with haloperidol for the treatment of schizophrenic psychosis. Twelve hospitalized schizophrenic patients were taken off their antipsychotic medication for 2 to 4 weeks before double-blind treatment with haloperidol (20 mg/day) combined with either clonidine or placebo. The group receiving clonidine was significantly more improved on the thought disorder subscale of the Brief Psychiatric Rating Scale (p = 0.02). The groups differed initially in the level of negative symptoms, but controlling for this difference statistically by analysis of covariance did not change the finding with regard to the superiority of combining clonidine with haloperidol. We conclude that larger treatment trials of combining haloperidol with clonidine are warranted.

AB - Because of the evidence for increased norepinephrine (NE) production in psychotic patients, we studied the effects of combining the α2-adrenergic agonist clonidine with haloperidol for the treatment of schizophrenic psychosis. Twelve hospitalized schizophrenic patients were taken off their antipsychotic medication for 2 to 4 weeks before double-blind treatment with haloperidol (20 mg/day) combined with either clonidine or placebo. The group receiving clonidine was significantly more improved on the thought disorder subscale of the Brief Psychiatric Rating Scale (p = 0.02). The groups differed initially in the level of negative symptoms, but controlling for this difference statistically by analysis of covariance did not change the finding with regard to the superiority of combining clonidine with haloperidol. We conclude that larger treatment trials of combining haloperidol with clonidine are warranted.

UR - http://www.scopus.com/inward/record.url?scp=0028879488&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028879488&partnerID=8YFLogxK

U2 - 10.1097/00004714-199510000-00009

DO - 10.1097/00004714-199510000-00009

M3 - Article

VL - 15

SP - 361

EP - 364

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 5

ER -